GREENWOOD, Colo., April 1, 2020 (Newswire.com) - ANANDA Scientific, a biotech pharma company, today announced that its clinical research team will initiate trials to assess the company´s proprietary Liquid Structure™ Cannabidiol (CBD) formulation as a treatment for mitigating the impact of COVID-19 infections, specifically, the “cytokine storms” that result from an excessive production of immune system proteins and are a major cause of severe respiratory distress, other...
Read More